Matches in SemOpenAlex for { <https://semopenalex.org/work/W151420841> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W151420841 abstract "The majority of non-small cell lung cancer (NSCLC) patients present with advanced disease and with a 5 year survival rate of <15% for these patients, treatment outcomes are considered extremely disappointing. Standard chemotherapy regimens provide some improvement to ~40% of patients. However, intrinsic and acquired chemoresistance are a significant problem and hinder sustained long term benefits of such treatments. Advances in proteomic and genomic profiling have increased our understanding of the aberrant molecular mechanisms that are driving an individual's tumour. The increased sensitivity of these technologies has enabled molecular profiling at the stage of initial biopsy thus paving the way for a more personalised approach to the treatment of cancer patients. Improvements in diagnostics together with a wave of new targeted small molecule inhibitors and monoclonal antibodies have revolutionised the treatment of cancer. To date there are essentially three targeted agents approved for clinical use in NSCLC. The tyrosine kinase inhibitor (TKI) erlotinib, which targets the epidermal growth factor receptor (EGFR) TK domain, has proven to be an effective treatment strategy in patients who harbour activating mutations in the EGFR TK domain. Bevacizumab a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) can improve survival, response rates, and progression-free survival when used in combination with chemotherapy. Crizotinib, a small-molecule drug, inhibits the tyrosine kinase activity of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) fusion protein, resulting in decreased tumour cell growth, migration, and invasiveness in patients with locally advanced or metastatic NSCLC. The clinical relevance of several other targeted agents are under investigation in distinct molecular subsets of patients with key driver mutations including: KRAS, HER2, BRAF, MET, PIK3CA, AKT1,MAP2K1, ROS1 and RET. Often several pathways are activated simultaneously and crosstalk between pathways allows tumour cells to escape the inhibition of a single targeted agent. This chapter will explore the clinical development of currently available targeted therapies for NSCLC as well as those in clinical trials and will examine the synergy between cytotoxic therapies." @default.
- W151420841 created "2016-06-24" @default.
- W151420841 creator A5011765580 @default.
- W151420841 creator A5033519199 @default.
- W151420841 creator A5053327309 @default.
- W151420841 date "2013-05-01" @default.
- W151420841 modified "2023-09-24" @default.
- W151420841 title "Targeted therapies in non-small cell lung cancer" @default.
- W151420841 hasPublicationYear "2013" @default.
- W151420841 type Work @default.
- W151420841 sameAs 151420841 @default.
- W151420841 citedByCount "0" @default.
- W151420841 crossrefType "book-chapter" @default.
- W151420841 hasAuthorship W151420841A5011765580 @default.
- W151420841 hasAuthorship W151420841A5033519199 @default.
- W151420841 hasAuthorship W151420841A5053327309 @default.
- W151420841 hasConcept C117643217 @default.
- W151420841 hasConcept C121608353 @default.
- W151420841 hasConcept C126322002 @default.
- W151420841 hasConcept C143998085 @default.
- W151420841 hasConcept C170493617 @default.
- W151420841 hasConcept C2776232967 @default.
- W151420841 hasConcept C2776256026 @default.
- W151420841 hasConcept C2776694085 @default.
- W151420841 hasConcept C2777802072 @default.
- W151420841 hasConcept C2778087573 @default.
- W151420841 hasConcept C2778820342 @default.
- W151420841 hasConcept C2779422266 @default.
- W151420841 hasConcept C2779438470 @default.
- W151420841 hasConcept C2781230642 @default.
- W151420841 hasConcept C42362537 @default.
- W151420841 hasConcept C502942594 @default.
- W151420841 hasConcept C71924100 @default.
- W151420841 hasConceptScore W151420841C117643217 @default.
- W151420841 hasConceptScore W151420841C121608353 @default.
- W151420841 hasConceptScore W151420841C126322002 @default.
- W151420841 hasConceptScore W151420841C143998085 @default.
- W151420841 hasConceptScore W151420841C170493617 @default.
- W151420841 hasConceptScore W151420841C2776232967 @default.
- W151420841 hasConceptScore W151420841C2776256026 @default.
- W151420841 hasConceptScore W151420841C2776694085 @default.
- W151420841 hasConceptScore W151420841C2777802072 @default.
- W151420841 hasConceptScore W151420841C2778087573 @default.
- W151420841 hasConceptScore W151420841C2778820342 @default.
- W151420841 hasConceptScore W151420841C2779422266 @default.
- W151420841 hasConceptScore W151420841C2779438470 @default.
- W151420841 hasConceptScore W151420841C2781230642 @default.
- W151420841 hasConceptScore W151420841C42362537 @default.
- W151420841 hasConceptScore W151420841C502942594 @default.
- W151420841 hasConceptScore W151420841C71924100 @default.
- W151420841 hasLocation W1514208411 @default.
- W151420841 hasOpenAccess W151420841 @default.
- W151420841 hasPrimaryLocation W1514208411 @default.
- W151420841 hasRelatedWork W1973327715 @default.
- W151420841 hasRelatedWork W2083711555 @default.
- W151420841 hasRelatedWork W2086293120 @default.
- W151420841 hasRelatedWork W2114419702 @default.
- W151420841 hasRelatedWork W2117461394 @default.
- W151420841 hasRelatedWork W2127344848 @default.
- W151420841 hasRelatedWork W2130354766 @default.
- W151420841 hasRelatedWork W2178746271 @default.
- W151420841 hasRelatedWork W2277685325 @default.
- W151420841 hasRelatedWork W2338583641 @default.
- W151420841 hasRelatedWork W2350346908 @default.
- W151420841 hasRelatedWork W2369409544 @default.
- W151420841 hasRelatedWork W2408381330 @default.
- W151420841 hasRelatedWork W2412672499 @default.
- W151420841 hasRelatedWork W2748626921 @default.
- W151420841 hasRelatedWork W2755895495 @default.
- W151420841 hasRelatedWork W2886005918 @default.
- W151420841 hasRelatedWork W2999103725 @default.
- W151420841 hasRelatedWork W3031955558 @default.
- W151420841 hasRelatedWork W3142205732 @default.
- W151420841 isParatext "false" @default.
- W151420841 isRetracted "false" @default.
- W151420841 magId "151420841" @default.
- W151420841 workType "book-chapter" @default.